To date, the most widely used molecular inhibitors in the treatment of ovarian cancer are the VEGF inhibitor bevacizumab and poly (ADP-ribose) polymerase (PARP) inhibitors. The gene discussed is VEGFA; the disease is ovarian carcinoma.